**Table S1**

List of trial inclusion and exclusion criteria for COV-HCQ, RECOVERY and SOLIDARITY clinical trialsa

|  |  |  |
| --- | --- | --- |
| COV-HCQ | SOLIDARITY | RECOVERY |
| Inclusion criteria | | |
| – Written informed consent  – PCR-confirmed COVID-19  – Age ≥18 years  – Women of childbearing age only: must agree to practice continuous effective contraception for the duration of the study (a method which results in a failure rate <1% per year)  – Disease severe enough to require hospitalization  – QTc interval <450 ms | – Consenting adults (age ≥18 years)  – Hospitalized with definite COVID-19  – Not already receiving any of the study drugs  – Without known allergy or contra-indications to any of them (in the view of the physician responsible for their care, e.g. serious chronic liver or heart disease or pregnancy)  – Without anticipated transfer within 72 h to a non-study hospital | Patients are eligible for the study if all of the following are true:  – Aged ≥18 years  – Hospitalized  – SARS-CoV-2 infection  – No medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he/she were to participate in the trial |
| Exclusion criteria | | |
| – Respiratory rate >24 breaths/min  – Pregnancy (tested with a pregnancy test) or lactation  – Weight <50 kg  – Haemodynamic/rhythm instability  – Type 1 acute myocardial infarction  – Use of concomitant medications that prolong the QT/QTc interval.  – Any regular concomitant medication which is contraindicated for use together with hydroxychloroquine  – Hypersensitivity to hydroxychloroquine, chloroquine or other 4-aminoquinolines  - Pre-existing retinopathy or maculopathy  - Known glucose-6-phosphate dehydrogenase deficiency (haemolytic anaemia, favism)  - Haematopoietic system diseases  - Myasthenia gravis  - Any other significant disease, disorder or finding which, in the opinion of the investigator, may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data | Exclusion from study entry: Patients will not be randomized if, in the view of the randomizing doctor, ANY of the AVAILABLE study drugs are contra-indicated (e.g. because of patient characteristics, chronic liver or heart disease, or some concurrent medication) | Hydroxychloroquine:  – Known prolonged QTc interval  – Caution: co-administration with medications that prolong the QT interval (e.g. macrolides, quinolones) is not an absolute contraindication, but it may be appropriate to check the QT interval by performing an electrocardiogram |

PCR, polymerase chain reaction; COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2.

aCriteria for the respective clinical trials were obtained from the following sources:

COV-HCQ: <https://www.clinicaltrials.gov/ct2/show/NCT04342221?term=2020-001224-33&cond=Covid19&draw=2&rank=1>

SOLIDARITY: https:// www.who.int/publications/m/item/ a-coordinated-global-research-roadmap

(Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results, 2021)

RECOVERY: https://clinicaltrials.gov/ct2/show/NCT04381936

(RECOVERY Collaborative Group et al., 2020)